Introduction
============

Hypertension remains a major public health problem that is associated with considerable morbidity and mortality.^[@bib1]^ The rate of decline in heart rate (HR) after exercise (HR recovery, or HRR) reflects the status of vagal tone activation and sympathetic tone withdraw post exercise. Lower HRR represents an autonomous imbalance and is related to a worse cardiovascular outcome.^[@bib2]^ Previous studies have shown reduced HRR in hypertensive patients.^[@bib3],\ [@bib4]^ The impact of BP control on HRR in hypertensive patients is not fully understood. Beta-blockers are widely used to lower BP in hypertensive patients and exert a direct impact on HR. Previous studies have shown that HRR maintained its prognostic value in heart failure patients, regardless of beta-blocker use.^[@bib5]^ Karnik *et al.*^[@bib6]^ demonstrated that beta-blockers do not affect HRR in patients with a negative exercise stress echocardiography result and that HRR may be used for mortality prediction in these patients. HRR is improved in the presence of beta-blockers in patients with a positive exercise stress echocardiography result.^[@bib6]^ The impact of beta-blockers on hypertensive patients has not been reported. The present study compared the HRR between hospitalized normotensive subjects and hypertensive patients and between hypertensive patients with controlled and uncontrolled BP in the absence and presence of beta-blockers.

Patients and methods
====================

Study population
----------------

A total of 279 consecutive hospitalized patients with (*n*=140) and without (*n*=139) diagnoses of essential hypertension who underwent treadmill exercise tests and achieved the submaximal goal HR \[(220−age) × 0.85\] during May 2012 to March 2016 were included in this retrospective study. Patients with acute coronary syndrome, old myocardial infarction, complete left bundle branch block, WPW syndrome, atrial fibrillation, valvular heart disease and known non-ischemic cardiomyopathy were excluded. Patients treated with digitalis were also excluded. The local hospital ethics committee approved the study protocol, and written consent was obtained from each participating patient. All hypertensive patients received antihypertensive medication. Venous blood samples were obtained for lipid measurements following an overnight fast.

Treadmill exercise test
-----------------------

The treadmill exercise test was performed as previously described on a GE T2100 treadmill machine equipped with CASE6.5 software and exercise ECG test system according to the ACC/AHA 2002 guideline update for exercise testing.^[@bib7]^ Symptom-limited Bruce\'s protocol was used, and a surface 12-lead ECG was continuously monitored. BP was measured and recorded at rest, the end of each stress stage, peak stress, and recovery until six minutes after exercise or ST segment returned to the baseline level.^[@bib8],\ [@bib9]^ The exercise was stopped at the time of submaximal goal HR \[(220−age) × 0.85\]. The treadmill test was performed according to the Bruce plan: the initial speed was of the treadmill was 1.7 km h^−1^, slope 10° the second speed was 2.5 km h^−1^, slope 12° the third speed was 3.4 km h^−1^, slope 14° and the fourth speed was 4.2 km h^−1^, slope 16°. The speed increased every 3 min. HR and BP at rest and after exercise were measured in a sitting position using the method proposed by the American Heart Association.^[@bib10]^ HRR1 for the treadmill exercise test was the difference between the maximum HR in motion and the HR one minute after the test. Abnormal HRR1 was defined as ⩽24 beats per minute.^[@bib11]^ The HR and HRR at 2, 3, 4 and 5 min after exercise were also analyzed.

[Figure 1](#fig1){ref-type="fig"} shows HR and HRR changes after exercise.^[@bib4]^ The overall kinetics of HR or HRR during the transition from exercise peak to rest 1--5 min was described using the following mono-exponential function:^[@bib4]^

where *a*0 is the pre-recovery value of HR (or HRR) of exercise peak and *a*1 is the amplitude of the change in HR (or HRR) from *a*0. T is the recovery time constant (mean response time) and represents the time required to attain 63% of the steady-state amplitude. The model parameters were estimated using least-squares nonlinear regression, in which the best fit was defined by minimizing the residual sum of squares and minimal variation of residuals.

Follow-up
---------

Patients were followed up for 3--48 months, with an average follow-up time of 18.8±11.7 months, by phone call or home/clinic visit.

Statistical analysis
--------------------

Continuous data are expressed as the mean±standard deviation. Student\'s *t*-test was used for comparisons between groups. The chi-square test was used to compare the rates. The risk factors for hypertension were determined using multivariate logistic regression model after adjusting for age and gender. *P*-values \<0.05 were considered statistically significant. Statistical analyses were performed using IBM SPSS 19.0 software (Armonk, NY, USA).

Results
=======

Clinical features of patients in N-HP and HP groups
---------------------------------------------------

[Table 1](#tbl1){ref-type="table"} shows the clinical characteristics between N-HP and HP patients. Body mass index (BMI), triglyceride level and incidence of DM were significantly higher in the HP group than in the N-HP group, and HDL-c and HRR were significantly lower. BP was significantly higher in the HP group than the N-HP group before treadmill exercise, at peak exercise and 1 and 5 min post exercise. HR was significantly higher and HRR was significantly lower in the HP group than the N-HP group at 1--5 min after exercise. The percent of manual labour was similar between the N-HP and HP groups, and education status was better in the HP group than in the N-HP group.

Multiple regression analysis showed that history of DM, higher BMI, TG values, education level, and reduced HRR post exercise were risk factors and that higher HDL-c was a protective factor of HP after adjusting for gender and age ([Table 2](#tbl2){ref-type="table"}). [Figure 1a and b](#fig1){ref-type="fig"} show the HR and HRR changes post exercise in the N-HP and HP groups.

Clinical features and risk factor comparison between N-HP and HP patients with normal and reduced HRR
-----------------------------------------------------------------------------------------------------

[Table 3](#tbl3){ref-type="table"} shows the clinical features of N-HP and HP patients with normal or reduced HRR. Male gender, smoking, BMI and creatinine values were higher in non-HP subjects, and CHOL and HDL-c values were lower in the reduced HRR group compared with the normal HRR group. TG was higher in HP subjects, while LDL-c and HDL-c were lower in the reduced HRR group compared to the normal HRR group.

Clinical features of hypertensive patients with controlled and uncontrolled BP
------------------------------------------------------------------------------

The incidence of smokers, CCB use and patients with reduced HRR were significantly higher in hypertensive patients with uncontrolled BP compared with hypertensive patients with controlled BP. The incidence of monotherapy was higher and ⩾3 drug therapy regimens was lower in hypertensive patients with controlled BP compared with hypertensive patients with uncontrolled BP. HRR1, HRR3 and HRR5 were significantly lower and peak exercise BP and BP at 1 min post exercise was significantly higher in hypertensive patients with uncontrolled BP compared to hypertensive patients with controlled BP. The percentages of manual labour occupation and education level were similar between hypertensive patients with uncontrolled and controlled BP ([Table 4](#tbl4){ref-type="table"}). [Figures 1c and d](#fig1){ref-type="fig"} show the HR and HRR changes post exercise in hypertensive patients with controlled and uncontrolled BP.

Clinical features of hypertensive patients with or without beta-blockers
------------------------------------------------------------------------

We divided the hypertensive patients into without beta-blockers group and with beta-blockers group to observe the potential impact of beta-blockers on HRR in hypertensive patients ([Table 5](#tbl5){ref-type="table"}). Our results demonstrated that the clinical characteristics, including HRR, were comparable between the groups, which suggest that HRR was not significantly affected by beta-blockers in hypertensive patients.

Follow-up results
-----------------

Two patients were lost to follow-up, one patient in the HP group and the other in the N-HP group. There were no deaths or acute myocardial infarctions during the follow-up. Three of the 97 patients (3.1%) in the N-HP group with normal HRR and two of the 41 patients (4.9%) in the N-HP group with reduced HRR were hospitalized due to cardiac reasons. Three of the 74 patients (4.1%) in the HP group with normal HRR and three of the 65 patients (4.6%) in the HP group with reduced HRR were hospitalized due to cardiac reasons. The incidence of re-hospitalization due to cardiac reasons was similar among groups.

Discussion
==========

This study found that HRR was significantly lower in hypertensive patients compared with non-hypertensive patients. HRR was also significantly lower in hypertensive patients with uncontrolled BP compared with hypertensive patients with controlled BP. Our data indicate that more intensive BP control is essential to improve the autonomous balance and outcome for hypertensive patients and HRR, which is an inexpensive and easily available biomarker. HRR should be monitored to guide anti-hypertensive therapy. To the best of our knowledge, this study is the first report describing the association between HRR and BP in hypertensive patients receiving anti-hypertensive therapy.

Reduced HRR and hypertension
----------------------------

The present study found that HRR was reduced in hospitalized patients with hypertension compared with hospitalized patients without hypertension, which is consistent with previous studies.^[@bib3],\ [@bib4]^ Multiple regression analysis demonstrated that besides history of DM, higher BMI and TG values, reduced HRR1--HRR5 were also important risk factors of hypertension after adjusting for gender and age. Notably, our results showed that HRR1, HRR3 and HRR5 were significantly lower in hypertensive patients with uncontrolled BP than in hypertensive patients with controlled BP. This novel finding suggests that optimal BP after anti-hypertensive medication is related to an improved sympathetic/vagal balance in hypertensive patients. As expected, the percent of patients using a combined drug therapy regimen was higher in hypertensive patients with uncontrolled BP, and the percent of monotherapy use was more often seen in hypertensive patients with controlled BP. These results indicate that the sympathetic/vagal imbalance in patients with uncontrolled BP might serve as a reason for the uncontrolled BP despite the use of medications according to the current guideline.^[@bib12]^ Strategies that aim to improve sympathetic/vagal imbalance might be important to treat patients with uncontrolled BP in addition to guideline-conforming antihypertensive medications.

Risk stratification for patients with severe cardiovascular diseases, such as in chronic heart failure patients (NYHA II or III) with left ventricular ejection fraction ⩽40%^[@bib13]^ could be already made by lower HRR (⩽18 per minute), and higher HRR might be applicable to patients with relatively 'mild\' cardiovascular diseases, as in the case of uncomplicated essential hypertension shown in this study and in patients with stable heart failure (⩽24/minute).^[@bib14]^ The mean HRR in the present study cohort was 31±10 for non-hypertensive patients and 26±8 for hypertensive patients. We used HRR ⩽24 beats/minute as the cutoff value for HRR, following Gharacholou *et al.*^[@bib11]^ We examined the results by defining HRR ⩽18 beats per minute as the cutoff value for HRR and found that abnormal HRR was 11.5% in the non-hypertension group and 20.0% in the hypertension group. Abnormal HRR was 18.2% in the BP controlled group and 23.1% in the BP uncontrolled group.

Potential impact of beta-blockers, gender, smoking, BMI, triglyceride level, manual labour occupation, and education status on HRR in hypertensive patients
-----------------------------------------------------------------------------------------------------------------------------------------------------------

Previous studies explored the potential impact of beta-blockers on HRR in heart failure patients^[@bib5]^ and ischemic patients,^[@bib6]^ but studies investigating the impact of beta-blockers on HRR in hypertensive patients are scant. Our results showed comparable results between hypertensive patients receiving beta-blockers and hypertensive patients who were not treated with beta-blockers ([Table 5](#tbl5){ref-type="table"}), which suggest that HRR post exercise was not significantly affected by beta-blockers in this patient cohort.

As there were 19% more smokers and 14% more males in the uncontrolled hypertensive group compared to the hypertensive patients with controlled BP group, gender and smoking status might be linked to the reduced HRR in the uncontrolled hypertensive group. We examined the HRR after adjusting for gender and smoking, and the results showed that HRR1 ⩽24 remained a risk factor for uncontrolled BP ([Table 6](#tbl6){ref-type="table"}). Therefore, the difference in HRR between hypertensive patients with controlled and uncontrolled BP is unlikely induced by gender and smoking. Notably, the BMI was significantly higher in hypertensive patients compared to non-hypertensive patients, but the BMI was near the normal range in this study patient cohort. Therefore, caution is required in the interpretation of the present data, and future studies are warranted to explore the association between HRR and hypertension, including goal BP control in obese hypertensive patients. Our results showed relatively high triglyceride levels, although 67--75% of the patients received a lipid-lowering medication (statin). the underlying reasons for this result are not fully clear, but poor drug compliance might be a possible reason for this result. Another factor might be the impact of dietary habits because dietary carbohydrate content is generally very high in the Chinese population, which might be another reason to explain the high triglyceride levels despite statin use. Future studies should explore the lipid-lowering efficacy of statins in various dietary plans. The percent of patients with a manual labour occupation was similar between the N-HP and HP groups. Therefore, the impact of manual labour occupations on the development of hypertension in this patient cohort might be minimal. The education level was slightly higher in the HP group compared to the N-HP group. The underlying reasons for higher hypertension in this small study cohort could not be explained, and it is beyond the scope of the present study. The percentages of labour occupation and education level were similar between hypertensive patients with controlled and uncontrolled BP. Therefore, these factors might not be related to the lower HRR found in hypertensive patients with uncontrolled BP.

Clinical implications
---------------------

The present study suggests that reduced HRR, which is a simple and inexpensive biomarker, is related to hypertension and reflects suboptimal BP control in hypertensive patients. Therefore, monitoring HRR during antihypertensive therapy might be an essential strategy to improve the autonomous balance and outcome for hypertensive patients.

Study limitations
-----------------

First, the present retrospective study results were derived from a small patient cohort based on a single center database. Our results need to be validated by a larger patient cohort from multi-center database. Second, the outcome during the short-term (18.8±11.7 months) follow-up was similar among groups. A longer follow-up period is warranted to observe the impact of reduced HRR on outcomes in this patient cohort. Third, a prospective study is needed to explore the impact of intensive BP control on HRR and outcome in hypertensive patients. Notably, HRR could be affected by aerobic fitness, and the lower HRR in hypertensive patients with uncontrolled BP compared to hypertensive patients with controlled BP might reflect differences in aerobic fitness. The present study could not clarify this issue because of the lack of some data, such as VO~2~ peak derived from cardiopulmonary exercise tests. Future studies are warranted to clarify this issue using cardiopulmonary exercise tests. The resting HR was relatively high (\~80 per minute) in the N-HP and HP groups, although beta-blockers were prescribed to approximately 30% of the patients without hypertension and 50% of the hypertensive patients. Mental stress before the treadmill exercise test might play a minor role in these subjects, but this factor could not be confirmed in this study. Medication compliance might be another difficult-to-confirm issue for the relatively high resting HR in the study subjects. Although all patients confirmed their prescribed medications by answering the questionnaire sheets, we could not confirm whether individual patients actually took their prescribed medication.

Conclusions
===========

The present results show that uncontrolled BP post antihypertensive medication is associated with lower HRR in hypertensive patients. Monitoring HRR might be an important strategy to optimize therapeutic efficacy by focusing on improving autonomous balance and outcome for hypertensive patients.
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###### Clinical characteristic of N-HP patients and HP patients

                                        *N-HP (*n=*139)*   *HP (*n=*140)*    P*-value*
  ------------------------------------ ------------------ ----------------- -----------
  Age (yr)                                 57.17±6.14        58.72±7.29        0.056
  Male gender (*n*, %)                   49/139 (35.3%)    58/140 (41.4%)      0.289
  BMI (kg/m^2^)                            23.16±3.43        25.18±3.48        0.000
  Smoker (*n*, %)                        32/139 (23.0%)    45/140 (32.1%)      0.088
  Manual labour (*n*, %)                 84/139 (60.4%)    90/140 (64.3%)      0.506
  *Education (*n, *%)*                                                         0.013
   Primary school and below (*n*, %)     29/139 (20.9%)     12/140 (8.6%)         
   Middle school (*n*, %)                44/139 (31.7%)    46/140 (32.9%)         
   High school (*n*, %)                  56/139 (40.3%)    62/140 (44.3%)         
   University and above (*n*, %)         10/139 (7.2%)     20/140 (14.3%)         
  CAD (*n*, %)                           47/139 (33.8%)    45/140 (32.1%)      0.767
  DM (*n*, %)                            12/139 (8.6%)     27/140 (19.3%)      0.010
  Dyslipidemia (*n*, %)                 102/139 (73.4%)    116/140 (82.9%)     0.056
  Creatinine (μ[M]{.smallcaps})           64.89±14.34        66.18±14.71       0.459
  CHOL (m[M]{.smallcaps})                  4.89±0.94          4.75±1.07        0.235
  TG (m[M]{.smallcaps})                    1.59±1.37          2.14±1.71        0.003
  LDL-c (m[M]{.smallcaps})                 2.95±0.80          2.84±0.98        0.294
  HDL-c (m[M]{.smallcaps})                 1.20±0.37          1.07±0.32        0.001
  HR before Ex (b.p.m.)                   79.68±11.58        80.91±12.21       0.386
  Peak HR (b.p.m.)                        141.73±6.95        140.46±7.17       0.134
  HR1 (b.p.m.)                            110.55±11.88      114.54±10.11       0.003
  HRR1 (b.p.m.)                           31.19±10.43        25.92±7.86        0.000
  HRR1 ⩽24 b.p.m. (*n*, %)               41/139(29.5%)     65/140 (46.4%)      0.004
  HR2 (b.p.m.)                            91.63±12.41        96.19±13.32       0.003
  HRR2 (b.p.m.)                           50.09±11.88        44.27±11.49       0.000
  HRR2 ⩽42 b.p.m. (*n*, %)               34/139 (24.5%)    63/140 (45.0%)      0.000
  HR3 (b.p.m.)                            86.81±11.05        90.25±12.57       0.016
  HRR3 (b.p.m.)                           54.91±11.10        50.21±11.20       0.000
  HR4 (b.p.m.)                            84.76±10.39        87.63±11.85       0.032
  HRR4 (b.p.m.)                           56.97±10.61        52.83±10.80       0.001
  HR5 (b.p.m.)                            83.72±10.22        86.38±11.97       0.047
  HRR5 (b.p.m.)                           58.01±10.59        54.08±10.80       0.002
  SBP before Ex (mm Hg)                   119.47±12.27      130.49±14.34       0.000
  DBP before Ex (mm Hg)                    75.43±8.19        80.76±8.93        0.000
  SBP peak (mm Hg)                        156.30±22.96      175.13±20.20       0.000
  DBP peak (mm Hg)                        73.50±11.23        80.20±11.33       0.009
  SBP at 1 min post Ex (mm Hg)            134.66±18.06      150.11±21.39       0.000
  DBP at 1 min post Ex (mm Hg)             75.42±7.75        79.39±10.09       0.016
  SBP at 5 min post Ex (mm Hg)            124.65±17.84      138.26±16.77       0.000
  DBP at 5 min post Ex (mm Hg)             76.25±7.57        80.94±9.50        0.000
  Time for Ex (minute)                     4.52±1.86          4.24±1.72        0.203
  Exercise tolerance (Mets)                6.34±1.69          6.36±1.77        0.911
  Ejection fraction medication             0.62±0.06          0.63±0.07        0.541
   Aspirin use (*n*, %)                  77/139 (55.4%)    90/140 (64.2%)      0.130
   Statin use (*n*, %)                   92/139 (66.2%)    98/140 (70.0%)      0.494
   Bata-blockers use (*n*, %)            42/139 (30.2%)    70/140 (50.0%)      0.001
   ACEI use (*n*, %)                      6/139 (4.3%)     39/140 (27.9%)      0.000
   ARBs use (*n*, %)                      0/139 (0.0%)     41/140 (29.3%)      0.000
   CCB use (*n*, %)                      16/139 (11.5%)    93/140 (66.4%)      0.000
   Diuretics use (*n*, %)                 0/139 (0.0%)      12/140 (8.6%)      0.000

Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; BMI, body mass index; CAD, coronary artery disease; CCB, Calcium Channel Blockers; CHOL, cholesterol; DBP, diastolic blood pressure; DM, diabetes mellitus; Ex, treadmill exercise; HDL-c, high density lipoprotein cholesterol; HP, hypertensive; HR, heart rate; HRn, heart rate at n minute post exercise; HRR, heart rate recovery; HRRn, heart rate recovery at n minute post exercise; LDL-c, low density lipoprotein cholesterol; Mets, metabolic equivalents (1MET=3.5 ml kg^−1^ per minute of oxygen consumption); N-HP, normotensive; SBP, systolic blood pressure; TG, triglyceride; yr, year.

###### Multivariate logistic regression results for risk of HP

                                   *B*      *s.e.*   *Wald*   P*-value*   *Exp*   *95% CI lower limit*   *95% CI upper limit*
  -------------------------------- -------- -------- -------- ----------- ------- ---------------------- ----------------------
  BMI (kg m^−2^)                   0.194    0.041    22.600   0.000       1.214   1.121                  1.316
  Education                                          10.345   0.016                                       
   Middle school (*n*, %)          0.930    0.407    5.215    0.022       2.534   1.141                  5.629
   High school (*n*, %)            1.062    0.397    7.137    0.008       2.891   1.327                  6.229
   University and above (*n*, %)   1.613    0.534    9.116    0.003       5.018   1.761                  14.296
  DM (*n*, %)                      0.951    0.377    6.357    0.012       2.588   1.236                  5.422
  TG (mM)                          0.321    0.108    8.834    0.003       1.379   1.116                  1.704
  HDL-c (mM)                       −1.221   0.405    9.116    0.003       0.295   0.133                  0.651
  HRR1 (b.p.m.)                    0.059    0.015    16.196   0.000       1.061   1.031                  1.092
  HRR1 ⩽24 (%)                     0.653    0.258    6.389    0.011       1.921   1.158                  3.188
  HRR2 (b.p.m.)                    0.043    0.012    13.162   0.000       1.044   1.020                  1.068
  HRR2 ⩽42 (%)                     0.959    0.278    11.860   0.001       2.608   1.512                  4.501
  HRR3 (b.p.m.)                    0.036    0.012    8.887    0.003       1.036   1.012                  1.060
  HRR4 (b.p.m.)                    0.033    0.012    7.221    0.007       1.034   1.009                  1.059
  HRR5 (b.p.m.)                    0.031    0.012    6.459    0.011       1.032   1.007                  1.057

Abbreviations: BMI, body mass index; CI, confidence interval; DM, diabetes mellitus; HDL-c, high-density lipoprotein cholesterol; HP, hypertensive; HRR, heart rate recovery; HRRn, heart rate recovery at n minute post exercise; TG, triglyceride.

###### Clinical characteristics of N-HP and HP patients with normal HRR1 and abnormal HRR1

                                       *N-HP*          *HP*                              
  ------------------------------------ --------------- ----------------- --------------- ------------------
  Age (yr)                             56.82±5.95      58.02±6.56        58.51±7.30      58.97±7.33
  Male gender (*n*, %)                 28/98 (28.6%)   21/41 (51.2%)\*   26/75 (34.7%)   32/65 (49.2%)
  BMI (kg m^−2^)                       22.78±3.63      24.07±2.71\*      24.94±3.50      25.46±3.48
  Smoker (*n*, %)                      18/98 (18.4%)   14/41(31.4%)\*    19/75 (25.3%)   26/65(31.4%)
  Manual labour (*n*, %)               56/98(57.1%)    28/41 (51.2%)     51/75 (68.0%)   39/65 (60.0%)
  *Education (*n, *%)*                                                                    
   Primary school and below (*n*, %)   23/98 (23.5%)   6/41 (14.6%)      7/75 (9.3%)     5/65 (7.7%)
   Middle school (*n*, %)              30/98 (30.6%)   14/41 (34.1%)     27/75 (36.0%)   19/65 (29.2%)
   High school (*n*, %)                40/98 (40.8%)   16/41 (39.0%)     31/75 (41.3%)   31/65 (47.7%)
   University and above (*n*, %)       5/98 (5.1%)     5/41 (12.2%)      10/75 (13.3%)   10/65 (15.4%)
  CAD (*n*, %)                         30/98 (30.6%)   17/41(41.5%)      21/75 (28.0%)   24/65 (40.0%)
  DM (*n*, %)                          8/98 (8.2%)     4/41(9.8%)        11/75(14.7%)    16/65 (24.6%)
  Dyslipidemia (*n*, %)                74/98 (75.5%)   28/41(68.3%)      62/75(82.6%)    54/65 (83.1%)
  Creatinine (μ[M]{.smallcaps})        62.21±12.99     71.31±15.50\*     64.92±14.21     67.63±15.24
  CHOL (m[M]{.smallcaps})              5.03±0.92       4.56±0.89\*       4.89±1.10       4.59±1.01
  TG (m[M]{.smallcaps})                1.43±0.92       1.98±2.05         1.95±1.80       2.37±1.59^†^
  LDL-c (m[M]{.smallcaps})             3.05±0.83       2.72±0.69         2.99±1.05       2.68±0.88^†^
  HDL-c (m[M]{.smallcaps})             1.27±0.39       1.06±0.25\*       1.13±0.30       1.01±0.32^†^
  HR before Ex (b.p.m.)                78.05±11.51     83.56±10.93\*     77.51±10.49     84.85±12.94^†^
  Peak HR (b.p.m.)                     141.93±6.74     141.24±7.51       141.03±6.94     139.80±7.42
  HR1 (b.p.m.)                         105.76±9.62     122.02±8.43\*     109.21±8.35     120.68±8.37^†^
  HR2 (b.p.m.)                         87.83±10.94     100.73±11.00\*    91.51±11.48     101.58±13.33^†^
  HRR2 (b.p.m.)                        54.10±10.63     40.51±8.95\*      49.52±9.71      38.22±10.40^†^
  HRR2 ⩽42  b.p.m. (*n*, %)            11/98 (11.2%)   23/41 (56.1%)\*   16/75 (21.3%)   47/65 (72.3%)^†^
  HR3 (b.p.m.)                         83.52±10.04     94.68±9.33\*      85.65±10.72     95.55±12.54^†^
  HRR3 (b.p.m.)                        58.41±10.07     46.56±8.83\*      55.37±9.72      44.25±9.80^†^
  HR4 (b.p.m.)                         82.34±9.62      90.54±9.98\*      83.60±9.52      92.28±12.61^†^
  HRR4 (b.p.m.)                        59.59±10.11     50.71±9.12\*      57.43±9.38      47.52±9.91^†^
  HR5 (b.p.m.)                         81.38±9.76      89.32±9.17\*      82.40±10.17     90.97±12.31^†^
  HRR5 (b.p.m.)                        60.55±10.51     51.93±8.07\*      58.63±9.53      48.83±9.79^†^
  SBP before Ex (mm Hg)                118.27±12.75    122.34±10.64      127.92±14.22    133.46±14.00^†^
  DBP before Ex (mm Hg)                74.74±8.49      77.07±7.26        80.03±9.02      81.62±8.82
  SBP peak (mm Hg)                     157.98±21.94    149.58±26.65      174.33±23.57    176.33±14.63
  DBP peak (mm Hg)                     73.81±11.13     72.25±12.05       81.00±21.25     79.00±10.19
  SBP at 1 min post Ex (mm Hg)         132.91±17.65    140.85±18.88      148.06±23.58    152.42±18.74
  DBP at 1 min post Ex (mm Hg)         74.96±7.96      77.08±6.99        80.00±10.79     81.18±8.39
  SBP at 5 min post Ex (mmHg)          123.33±17.81    127.84±17.74      136.29±18.67    139.88±15.04
  DBP at 5 min post Ex (mm Hg)         75.57±7.58      77.92±7.38        80.64±10.79     81.18±8.39
  Time for Ex (minute)                 4.40±1.74       4.79±2.11         4.29±1.71       4.20±1.74
  Exercise tolerance (Met)             6.19±1.60       6.70±1.88         6.41±1.65       6.31±1.90
  Ejection fraction medication         0.62±0.06       0.62±0.05         0.63±0.07       0.63±0.06
   Aspirin use (*n*, %)                54/98 (55.1%)   23/41 (56.1%)     49/75 (65.3%)   41/65 (63.1%)
   Statin use (*n*, %)                 68/98 (69.4%)   24/41 (58.5%)     50/75 (66.7%)   48/65 (73.8%)
   Beta-blockers (*n*, %)              29/98 (29.6%)   13/41 (31.7%)     36/75 (48.0%)   34/65 (52.3%)
   ACEI use (*n*, %)                   4/98 (4.1%)     2/41 (4.9%)       24/75 (32.0%)   15/65 (23.1%)
   ARBs use (*n*, %)                   0/98 (0.0%)     0/41 (0%)         20/75 (26.7%)   21/65 (32.3%)
   CCB use (*n*, %)                    10/98 (10.2%)   6/41 (14.6%)      47/75 (62.7%)   46/65 (70.8%)
   Diuretics use (*n*, %)              0/98 (0.0%)     0/41 (0%)         4/75 (5.3%)     8/65 (12.3%)

Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; BMI, body mass index; CAD, coronary artery disease; CCB, Calcium Channel Blockers; CHOL, cholesterol; DBP, diastolic blood pressure; DM, diabetes mellitus; Ex, treadmill exercise; HDL-c, high density lipoprotein cholesterol; HP, hypertensive; HR, heart rate; HRn, heart rate at n minute post exercise; HRR, heart rate recovery; HRRn, heart rate recovery at n minute post exercise; LDL-c, low density lipoprotein cholesterol; Mets, metabolic equivalents (1MET=3.5 ml kg^−1^ per minute of oxygen consumption); N-HP, normotensive; SBP, systolic blood pressure; TG, triglyceride; yr, year.

\**P*\<0.05 vs N-HP normal HRR; †*P*\<0.05 vs HP normal HRR.

###### Clinical characteristic of HP patients with controlled and uncontrolled BP

                                        *BP controlled (n*=*88)*   *BP uncontrolled (n*=*52)*   P*-value*
  ------------------------------------ -------------------------- ---------------------------- -----------
  Age (yr)                                     58.19±7.70                 59.62± 6.51             0.266
  Male gender (*n*, %)                       32/88 (36.4%)               26/52 (50.0%)            0.114
  BMI (kg m^−2^)                               25.16±3.58                  25.22±3.36             0.920
  Smoker (*n*, %)                            22/88 (25.0%)                23/52(44.2%)            0.019
  Manual labour (*n*, %)                     56/88 (63.6%)                34/52(67.3%)            0.835
  *Education (*n, *%)*                                                                            0.357
   Primary school and below (*n*, %)           7/88(8.0%)                 5/52 (9.6%)                
   Middle school (*n*, %)                    29/88 (33.0%)               17/52 (32.7%)               
   High school (*n*, %)                      36/88 (40.9%)               26/52 (50.0%)               
   University and above (*n*, %)             16/88 (18.2%)                4/52 (7.7%)                
  CAD (*n*, %)                               28/88 (31.8%)               17/52 (32.3%)            0.915
  DM (*n*, %)                                16/88 (18.2%)               11/52 (21.2%)            0.667
  Dyslipidemia (*n*, %)                      72/88 (81.8%)               44/52 (84.6%)            0.671
  Creatinine (μ[M]{.smallcaps})               66.27±14.68                 66.03±14.90             0.927
  CHOL(m[M]{.smallcaps})                       4.73±1.14                   4.77±0.95              0.850
  TG (m[M]{.smallcaps})                        2.10±1.69                   2.22±1.77              0.677
  LDL-c (m[M]{.smallcaps})                     2.82±1.06                   2.87±0.83              0.758
  HDL-c (m[M]{.smallcaps})                     1.10±0.33                   1.02±0.29              0.170
  HR before Ex (b.p.m.)                       79.82±12.13                 82.77±12.24             0.168
  Peak HR (b.p.m.)                            140.84±7.40                 139.81±6.78             0.412
  HR1 (b.p.m.)                                113.71±10.44                115.92±9.46             0.213
  HRR1 (b.p.m.)                                27.13±7.59                  23.88±7.96             0.018
  HRR1 ⩽24  b.p.m. (%)                        33/88(37.5%)                32/52(61.5%)            0.006
  HR2 (b.p.m.)                                95.18±12.27                 97.88±14.90             0.247
  HRR2 (b.p.m.)                                45.66±9.42                 41.92±14.12             0.093
  HRR2 ⩽42  b.p.m. (%)                       37/88 (42.05%)              26/52 (50.00%)           0.361
  HR3 (b.p.m.)                                88.86±12.03                 92.60±13.23             0.090
  HRR3 (b.p.m.)                                51.98±9.76                 47.21±12.84             0.014
  HR4 (b.p.m.)                                86.51±10.97                 89.52±13.09             0.147
  HRR4 (b.p.m.)                                54.33±9.10                 50.29±12.89             0.050
  HR5 (b.p.m.)                                85.30±11.31                 88.21±12.91             0.164
  HRR5 (b.p.m.)                                55.55±9.41                 51.60±12.51             0.036
  SBP before Ex (mm Hg)                       121.80±8.60                 145.21±9.09             0.000
  DBP before Ex (mm Hg)                        77.02±6.28                  87.10±9.22             0.000
  SBP peak (mm Hg)                            164.55±16.22                181.26±20.07            0.026
  DBP peak (mm Hg)                             70.82±8.40                  85.63±9.09             0.000
  SBP at 1 min post Ex (mm Hg)                144.07±19.70                166.31±19.62            0.001
  DBP at 1 min post Ex (mm Hg)                 77.93±9.40                 85.62±12.08             0.018
  SBP at 5 min post Ex (mm Hg)                132.42±17.22                138.60±32.99            0.249
  DBP at 5 min post Ex (mm Hg)                 77.68±7.62                 80.96±20.24             0.311
  Time for Ex (minute)                         4.30±1.69                   4.14±1.77              0.598
  Exercise tolerance (Mets)                    6.49±1.76                   6.16±1.78              0.286
  Ejection fraction                            0.63±0.07                   0.62±0.07              0.279
  *Medication*                                                                                       
   Aspirin use (*n*, %)                      53/88 (60.2%)               37/52 (71.1%)            0.192
   Statin use (*n*, %)                       59/88 (67.0%)               39/52 (75.0%)            0.321
   Bata-blockers use (*n*, %)                46/88 (52.3%)               24/52 (46.2%)            0.484
   ACEI use (*n*, %)                         23/88 (26.1%)               16/52 (30.8%)            0.555
   ARBs use (*n*, %)                         23/88 (26.1%)               18/52 (34.6%)            0.287
   CCB use (*n*, %)                          53/88 (60.2%)               40/52 (76.9%)            0.043
   Diuretics use (*n*, %)                     7/88 (8.0%)                 5/52 (9.6%)             0.979
   categories of drugs                                                                            0.039
    Monotherapy (*n*, %)                     35/88 (39.8%)               12/52 (23.1%)               
    Two drug therapy (*n*, %)                43/88 (48.9%)               27/52 (51.9%)               
    ⩾Three drug therapy (*n*, %)             10/88 (11.4%)               13/52 (25.0%)               

Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARBs, angiotensin receptor blocker; BP, blood pressure; BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel blocker; CHOL, cholesterol; DBP, diastolic blood pressure; DM, diabetes mellitus; Ex, treadmill exercise; HDL-c, high density lipoprotein cholesterol; HP, hypertensive; HR, heart rate; HRn, heart rate at n minute post exercise; HRR, heart rate recovery; HRRn, heart rate recovery at n minute post exercise; LDL-c, low density lipoprotein cholesterol; Mets, metabolic equivalents (1MET=3.5 ml kg^−1^ per minute of oxygen consumption); SBP, systolic blood pressure; TG, triglyceride; yr, year.

###### Clinical characteristic of HP patients with and without beta-blockers

                                        *Without beta-blockers (*n=*70)*   *With beta-blockers (*n=*70)*   P*-value*
  ------------------------------------ ---------------------------------- ------------------------------- -----------
  Age (yr)                                         58.29±7.41                       59.16±7.20               0.482
  Male gender (*n*, %)                           28/70 (40.0%)                     30/70 (42.9%)             0.731
  BMI (kg m^−2^)                                   25.85±3.25                       24.51±3.61               0.022
  Smoker (*n*, %)                                21/70 (30.0%)                     24/70 (34.3%)             0.587
  Manual labour (*n*, %)                         46/70 (65.7%)                     44/70 (62.9%)             0.724
  *Education (*n, *%)*                                                                                       0.316
   Primary school and below (*n*, %)              7/70 (10.0%)                      5/70 (7.1%)                 
   Middle school (*n*, %)                        18/70 (25.7%)                     28/70 (40.0%)                
   High school (*n*, %)                          35/70 (50.0%)                     27/70 (38.6%)                
   University and above (*n*, %)                 10/70 (14.3%)                     10/70 (14.3%)                
  CAD (*n*, %)                                   12/70 (18.6%)                     33/70 (47.1%)             0.000
  DM (*n*, %)                                    17/70 (24.3%)                     10/70 (14.3%)             0.134
  Dyslipidemia (*n*, %)                          60/70 (85.7%)                     56/70 (80.0%)             0.370
  Creatinine (μ[M]{.smallcaps})                   66.73±13.83                       65.63±15.61              0.659
  CHOL (m[M]{.smallcaps})                          4.78±0.94                         4.71±1.19               0.706
  TG (m[M]{.smallcaps})                            2.11±1.50                         2.18±1.92               0.822
  LDL-c (m[M]{.smallcaps})                         2.88±0.77                         2.80±1.15               0.637
  HDL-c (m[M]{.smallcaps})                         1.06±0.28                         1.09±0.35               0.514
  HR before Ex (b.p.m.)                           81.41±11.92                       80.41±12.57              0.630
  Peak HR (b.p.m.)                                140.91±6.84                       140.00±7.50              0.452
  HR1(b.p.m.)                                     114.59±9.68                      114.49±10.59              0.954
  HRR1 (b.p.m.)                                    26.33±7.06                       25.51±8.62               0.542
  HRR1 ⩽24  b.p.m. (%)                           31/70 (44.3%)                     34/70 (48.6%)             0.611
  HR2 (b.p.m.)                                    97.06±12.49                       95.31±14.14              0.441
  HRR2 (b.p.m.)                                   43.86±11.11                       44.69±11.92              0.671
  HRR2 ⩽42  b.p.m. (%)                           31/70 (44.3%)                     22/70 (31.4%)             0.865
  HR3 (b.p.m.)                                    90.73±12.35                       89.77±12.86              0.654
  HRR3 (b.p.m.)                                   50.19±11.18                       50.23±11.31              0.982
  HR4 (b.p.m.)                                    87.77±11.53                       87.49±12.24              0.887
  HRR4 (b.p.m.)                                   53.14±10.44                       52.51±11.21              0.732
  HR5 (b.p.m.)                                    85.99±11.43                       86.77±12.55              0.699
  HRR5 (b.p.m.)                                   54.93±10.51                       53.23±11.08              0.353
  SBP before Ex (mm Hg)                           131.36±15.16                     129.63±13.52              0.478
  DBP before Ex (mm Hg)                            81.37±8.93                       80.16±8.95               0.423
  SBP peak (mm Hg)                                181.36±19.98                     168.00±18.62              0.069
  DBP peak (mm Hg)                                82.06±11.75                       78.07±10.86              0.345
  SBP at 1 min post Ex (mm Hg)                    154.71±22.54                     144.90±19.05              0.062
  DBP at 1 min post Ex (mm Hg)                     80.17±9.80                       78.52±10.50              0.510
  SBP at 5 min post Ex (mm Hg)                    136.20±27.88                     134.58±24.35              0.736
  DBP at 5 min post Ex (mm Hg)                    81.50±15.95                       78.08±14.14              0.433
  Time for Ex (minute)                             4.14±1.61                         4.35±1.83               0.478
  Exercise tolerance (Mets)                        6.16±1.56                         6.57±1.94               0.177
  Ejection fraction                                0.63±0.06                         0.62±0.07               0.325
  *Medication*                                                                                                  
   Aspirin use (*n*, %)                          39/70 (55.7%)                     51/70 (72.9%)             0.034
   Statin use (*n*, %)                           47/70 (67.1%)                     51/70 (72.9%)             0.461
   ACEI use (*n*, %)                             20/70 (28.6%)                     19/70 (27.1%)             0.850
   ARBs use (*n*, %)                             27/70 (38.6%)                     14/70 (20.0%)             0.016
   CCB use (*n*, %)                              57/70 (81.4%)                     36/70 (51.4%)             0.000
   Diuretics use (*n*, %)                         9/70 (12.9%)                      3/70 (4.3%)              0.070

Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARBs, angiotensin receptor blocker; BP, blood pressure; BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel blocker; CHOL, cholesterol; DBP, diastolic blood pressure; DM, diabetes mellitus; Ex, treadmill exercise; HDL-c, high density lipoprotein cholesterol; HP, hypertensive; HR, heart rate; HRn, heart rate at n minute post exercise; HRR, heart rate recovery; HRRn, heart rate recovery at n minute post exercise; LDL-c, low density lipoprotein cholesterol; Mets, metabolic equivalents (1MET=3.5 ml kg^−1^ per minute of oxygen consumption); SBP, systolic blood pressure; TG, triglyceride; yr, year.

###### Multivariate logistic regression results for risk of uncontrolled BP

                  *B*     *s.e.*   *Wald*   P*-value*   *Exp*   *95% CI lower limit*   *95% CI upper limit*
  --------------- ------- -------- -------- ----------- ------- ---------------------- ----------------------
  HRR1 (b.p.m.)   0.040   0.027    2.157    0.142       1.041   0.987                  1.096
  HRR1 ⩽24 (%)    0.801   0.388    4.250    0.039       2.227   1.040                  4.768
  HRR3 (b.p.m.)   0.032   0.020    2.713    0.100       1.033   0.994                  1.074
  HRR4 (b.p.m.)   0.028   0.021    1.816    0.178       1.028   0.987                  1.071
  HRR5 (b.p.m.)   0.026   0.021    1.529    0.216       1.026   0.985                  1.068

Abbreviations: BP, blood pressure; CI, confidence interval; HRR, heart rate recovery; HRRn, heart rate recovery at n minute post exercise.
